---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-037882"
form_type: "8-K/A"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:03:55.900463+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience reports Q3 FYARRO sales $6M (+40% YoY); net loss $16.3M; PRECISION1 interim on track for Dec 2023

## Summary
- FYARRO sales $6.0M in Q3 2023, up 40% YoY from $4.2M; net loss $16.3M vs $14.5M.
- Cash, equivalents & investments $119.3M as of Sep 30, 2023, expected to fund operations into 2025.
- PRECISION1 interim analysis on first third of patients (n=40) on track for mid-December 2023.
- Dave Lennon appointed President and CEO in early October 2023.
- Phase 2 trials initiated for endometrial cancer (nab-sirolimus + letrozole) and neuroendocrine tumors.

## SEC filing metadata
- accession: 0001628280-23-037882
- form_type: 8-K/A
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000162828023037882/0001628280-23-037882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000162828023037882/aadi-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-037882
- JSON: https://secwatch.observer/filing/0001628280-23-037882.json
- Plain text: https://secwatch.observer/filing/0001628280-23-037882.txt

## Key facts
- Earnings Releases
  Whitehawk Therapeutics, Inc. reported the quarter ended September 30, 2023 results: revenue $6.0 million, net income $16.3 million.
  - Period: the quarter ended September 30, 2023
  - Revenue: $6.0 million
  - Net income: $16.3 million
  - Result: reported results
  source text: total revenue resulting from sales of FYARRO for the quarter ended September 30, 2023, was $6.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828023037882/0001628280-23-037882-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.